Skip to NavigationSkip to content

Top Ten most popular articles on Pharmafile.com this week

Published on 13/12/19 at 03:21pm

As the UK reels from the news that Boris Johnson and the Conservative Party have stormed the general election and will hold government for at least the next five years, check out our run-down of the top 10 most popular stories on Pharmafile.com this week.

10. South Korea jails executives for their role in Samsung Biologics fraud

Three executives of Samsung Electronics have been sentenced to jail for their role in committing fraud at its biotech affiliate Samsung Biologics.

9. Strong four-year follow-up data revealed for AbbVie's venetoclax combo in chronic lymphocytic leukaemia

AbbVie used the platform of the American Society of Hematology (ASH) conference to present four-year follow-up analysis data on venetoclax in combination with rituximab (VenR) in the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL).

8. Bristol-Myers Squibb drug boasts strong overall survival in acute myeloid leukaemia

Bristol-Myers Squibb took the opportunity at the 2019 American Society of Hematology (ASH) Annual Meeting to reveal new efficacy data on its candidate CC-486 in the maintenance treatment of front-line, newly diagnosed acute myeloid leukaemia (AML) in patients who have achieved remission with intensive induction chemotherapy.

7. FDA approves first three generic versions of Novartis' Gilenya for relapsing multiple sclerosis

The FDA has approved the first three generic versions of Novartis’ sphingosine 1-phosphate receptor modulator Gilenya (fingolimod) to treat adult patients for relapsing multiple sclerosis (MS).

6. Anti-vaxx movement complicit in 140,000 global measles deaths in 2018, mostly in children

Over 140,000 people died from measles last year, with most of them being children under five, according to World Health Organization (WHO) and the US Centers for Diseases Control and Prevention.

5. FDA investigating if carcinogen NDMA is in diabetes drug

The FDA is looking into if the diabetes drug metformin has unsafe levels of a cancer-causing chemical.

4. Janssen's Darzalex combo shows strong overall survival benefit at ASH 2019

Janssen has unveiled new Phase 3 data on the efficacy of Darzalex (daratumumab) when combined with bortezomib, melphalan and prednisone (D-VMP) in the treatment of newly diagnosed, transplant-ineligible multiple myeloma at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando.

3. Sanofi acquires biotech firm Synthorx for $2.5 billion

Sanofi has agreed to buy California-based biotechnology firm Synthrox, in a deal worth about $2.5 billion (£1.95 billion).

2. Sanofi to move away from diabetes and cardiovascular, as company shakeup continues

Sanofi has said it will stop investment and research into creating new diabetes and cardiovascular drugs, as part of the company’s ongoing internal review.

1. Pfizer and Sangamo’s haemophilia gene therapy shows increased factor VIII levels

Pfizer and Sangamo Therapeutics have revealed that their investigational gene therapy, SB-525, sustained increased factor VIII (FVIII) levels in patients with haemophilia A through to 44 weeks following treatment.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches